What is the market capitalization of Neurogene Inc.?

Neurogene Inc. (NGNE) has a market capitalization of approximately 414,325,844 USD.

How many ETFs hold NGNE?

NGNE is held by 15 ETFs tracked on Investir en Bourse.

Where can I buy NGNE in Canada?

NGNE can be purchased through any Canadian online broker including Wealthsimple, Questrade, Qtrade, or RBC Direct Investing.

NGNE

Neurogene Inc.

Neurogene Inc. (NGNE) is an American company in the healthcare sector, listed on NASDAQ. Market capitalization of 414 million USD (small-cap).

Details

Price26.22 USD

Market cap414.33 M USD

Payout ratio0.00%

ROE-37.25%

Debt / Equity3.84%

SectorHealthcare

Websiteneurogene.com

Updated 4h ago

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.